A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma
Sponsor: Sumitomo Pharma America, Inc.
This PHASE2 trial investigates Asthma and is currently completed. Sumitomo Pharma America, Inc. leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Sep 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beverly Hills, United States, Burke, United States, Dallas, United States, Medford, United States, Normal, United States, Oklahoma City, United States, Orange, United States, Orangeburg, United States, Portland, United States, Richmond, United States and 3 more location s